Gene test may help prevent deadly fungal infections in leukemia patients
NCT ID NCT03828773
First seen Dec 10, 2025 · Last updated Jun 20, 2026 · Updated 26 times
Summary
This study tests whether a genetic test can help decide which leukemia patients need a strong antifungal drug (posaconazole) to prevent serious mold infections during chemotherapy. About 410 adults with acute myeloid leukemia will be randomly assigned to receive the drug or a placebo, and their genetic risk will be used to guide treatment. The goal is to see if this personalized approach reduces infections without unnecessary side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Sint-Jan Hospital
RECRUITINGBruges, 8000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cantonal Hospital Aarau
RECRUITINGAarau, Aarau, 5001, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cantonal Hospital HFR
RECRUITINGFribourg, Canton of Fribourg, 1708, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ghent University Hospital
TERMINATEDGhent, Belgium, 9000, Belgium
-
Henri Mondor Hospital
RECRUITINGCréteil, Île-de-France Region, 94010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Basel
RECRUITINGBasel, Basel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Leuven (UZ Leuven)
RECRUITINGLeuven, 3000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital of Geneva (HUG)
RECRUITINGGeneva, Canton of Geneva, 1211, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital of Lausanne / Centre Hospitalier Universitaire Vaudois (CHUV)
RECRUITINGLausanne, Canton of Vaud, 1011, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Posaconazole (Noxafil), an antifungal drug
What this could lead to
If successful, this could show that using a genetic test to decide who gets antifungal prevention reduces dangerous mold infections in leukemia patients.
What could go wrong
This is an early-stage trial with 410 participants, so results may not apply to all patients. The drug can have side effects like liver issues or drug interactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.